CHORDOMES: Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Study Details
Study Description
Brief Summary
Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Chordoma Patients diagnosed with chordoma |
Other: Analysis Immunohistochemical
Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
|
Outcome Measures
Primary Outcome Measures
- Expression of PD-L1 [Baseline]
measured by immunohistochemical method
- Expression of CD8 [Baseline]
measured by immunohistochemical method
- Expression of CDX2 [Baseline]
measured by immunohistochemical method
- Expression of INSM1 [Baseline]
measured by immunohistochemical method
- Expression of FOXA1 [Baseline]
measured by immunohistochemical method
Secondary Outcome Measures
- Histological type of tumor [Baseline]
data collected in personal health records.
- Tumor location [Baseline]
data collected in personal health records.
- survival of patients after diagnosis with or without progression [Baseline]
data collected in personal health records.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients diagnosed with chordoma
-
Sufficient histological material available
-
Tumor expression of brachyury
Exclusion Criteria:
- Insufficient histological material
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | CHU de Saint-Etienne | Saint-Étienne | France |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Saint Etienne
Investigators
- Principal Investigator: Georgia KARPATHIOU, MD, CHU SAINT-ETIENNE
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20CH028